Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. (CDXS) on March 28, 2025. The filing reports a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $50,000 for Board service.
- Committee Retainer: $20,000 for Compensation Committee service.
- Initial Equity Grant: Restricted Stock Units (RSUs) valued at $200,000, calculated based on a closing stock price of $2.81 per share on March 28, 2025.
- Annual Equity Grant: Future annual grants of RSUs valued at $100,000.
Material Changes
The material change reported is the appointment of Cynthia Collins as a Class II director, effective immediately. She was also appointed to the Compensation Committee. The filing states there are no other arrangements or understandings regarding her appointment.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the company's business outlook. The document focuses solely on the qualifications of the new director and the terms of her compensation. Ms. Collins brings significant experience as a former CEO of Editas Medicine, Human Longevity Inc., and GenVec, Inc., and currently serves as Executive Chair and Interim CEO of Nutcracker Therapeutics, Inc.
Key Facts for Investor Verification
- Verify the impact of the new board composition on the company's strategic direction, particularly in biotechnology and gene therapy sectors.
- Confirm the vesting schedule of the initial $200,000 RSU grant, which vests in three equal annual installments.
- Review the company's stock price performance relative to the $2.81 valuation used for the initial grant.
- Check for any subsequent filings regarding the standard indemnification agreement mentioned as expected.